SecBot SecBot

ZURA

Zura Bio Ltd
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. E9· CIK 0001855644 Biotech & Drug Discovery
$3.57 +0.21 (+6.10%)
Oct 26 4:00 PM ET · prev $3.36
Market cap
$338.3M
Small cap
Consensus
Buy
93% Buy or better · 14 analysts
Median target
🔒 Subscribers only
Next earnings
Nov 18
in 23 days · EPS est. −$0.21
1 year
−9.3%
from $3.93 · Oct 27
30 days
−13.0%
from $4.10
52-week range
$3.36–7.04
−49% from high · low Oct 23
Avg volume 20D
4.64M
Oct 13 spike 24.44M
Short interest
9.37M
≈9.8% of shares · +0.3%
Days to cover
4.8
at average volume
Insider net
+$12.5M
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read BULLISH 2 reports · 90 days
Balance 0 bearish · 1 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/2 ·Next Earnings date, Nov 18, 2026
Strongest BULLISH Zura Bio reported Q2 2026 financial results with a net loss of $26.3M ($0.21/share), wider than the $16.0M…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $12.5M at an average $6.25. No open-market sales. Price is 43% below their cost.

  • InstitutionsBULLISH

    Q2 2026: 14 added (0 new), 8 trimmed or exited.

  • AnalystsBULLISH

    13 of 14 rate it Buy or better.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.193 → −$0.208 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest +0.3% to 9.37M shares. 4.8 days to cover, ≈9.8% of shares.

  • TrendDOWNTREND

    26% below its 50-day average. New closing low $3.36 on Oct 23.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.DOUBLED3,614,695$21.3M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED1,584,209$9.3M
STATE STREET CORPDOUBLED1,001,637$5.9M
VANGUARD CAPITAL MANAGEMENT LLCADD747,352$4.4M
GOLDMAN SACHS GROUP INCDOUBLED573,946$3.4M
MORGAN STANLEYTRIM505,953$3.0M
NORTHERN TRUST CORPDOUBLED500,086$3.0M
VANGUARD FIDUCIARY TRUST COADD406,450$2.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

14 analysts
Buy 93% rate it Buy or better
Strong Buy7Buy6Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Aug 12, 2026Wedbush
MAINTAIN
MAINTAINOutperform
Aug 12, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Jul 8, 2026William Blair
INITIATE
INITIATEOutperform
Jul 1, 2026Wedbush
REITERATE
REITERATEOutperform

Insider ledger

Form 4
$12.5M
bought · 1 insider
$0
sold · 0 insiders
−43.0%
vs their $6.25 cost
DateInsiderTypeValue
Jun 17, 2026
Nirula Ajay
Director
AWARD51,000 sh
Jun 17, 2026
Jarrett Jennifer
Director
AWARD51,000 sh
Jun 17, 2026
Thiara Parvinder
Director
AWARD51,000 sh
Jun 17, 2026
Becker Daniel J.
Director
AWARD51,000 sh
Jun 17, 2026
Munshi Amit
Director
AWARD51,000 sh
Jun 17, 2026
Schoch Steven J
Director
AWARD51,000 sh
Jun 17, 2026
Eisner Mark
Director
AWARD51,000 sh
Apr 1, 2026
Davis Kim
Chief Legal Officer
AWARD425,700 sh

Earnings setup

Estimates
Nov 18
reports in 23 days
−$0.21
EPS estimate, this quarter
−8%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.21-$0.24–-$0.18+2.1%$0.00
Next Q-$0.19-$0.25–-$0.11+2.6%$0.00
Current FY-$0.80-$0.91–-$0.62+0.9%$0.00
Next FY-$0.69-$0.99–-$0.21-0.7%$0.00

Short side

FINRA· Sep 30, 2026
9,365,853
shares short
+0.3%
vs prior settlement
4.8
days to cover
≈9.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 19, 2026 Earnings calendar
ZURA Q2 2026 Earnings Scheduled — 2026-08-19
Aug 17, 2026 SEC
Zura Bio filed an 8-K furnishing an updated corporate investor presentation (Exhibit 99.1) as Regulation FD…
8-K — Impact 5/10
Aug 11, 2026 SEC
Zura Bio reported Q2 2026 financial results with a net loss of $26.3M ($0.21/share), wider than the $16.0M loss in Q2…
8-K — Impact 6/10
Jul 1, 2026 SEC
Zura Bio filed an 8-K furnishing an updated corporate presentation (Exhibit 99.1) for investor meetings. The…
8-K — Impact 4/10
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
3,614,695 shares ($21.3M)
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — DOUBLED
1,584,209 shares ($9.3M)
Jun 17, 2026 Insider
Nirula Ajay was granted 51,000 shares
Director
Jun 17, 2026 Insider
Jarrett Jennifer was granted 51,000 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 18, 2026
Earnings date
ZURA Q3 2026 Earnings Scheduled — 2026-11-18
Recent
Aug 19, 2026
Earnings date
ZURA Q2 2026 Earnings Scheduled — 2026-08-19
Aug 12, 2026
Earnings date
ZURA Q2 2026 Earnings Scheduled — 2026-08-12
Jun 30, 2026
Short interest
Short Interest: ZURA up 57% to 9.2M shares
Settlement 2026-06-30 | Days to cover: 4.05 | ≈9.73% of shares outstanding (est.)
May 7, 2026
Earnings date
ZURA Q1 2026 Earnings Scheduled — 2026-05-07
May 6, 2026
Earnings date
ZURA Q1 2026 Earnings Scheduled — 2026-05-06

SecBot reports

7 filings · 1 bullish · 0 bearish · 6 neutral
All ZURA filing & press-release reports (7)